The number of pipeline Diabetes Care products in 2021 saw an 186% rise globally when compared to Diabetes Care pipeline products in 2020, according to GlobalData’s pipeline products database. This compares to an 15% rise for all pipeline medical devices in 2021 compared to 2020.

The global Diabetes Care Devices market was worth $20.90bn in 2020 and is expected to reach $22.58bn by 2025, according to GlobalData’s analysis.


Diabetes Care Devices pipeline products by categories: Glucose Monitoring has the most devices

Looking at the device categories of pipeline products, Glucose Monitoring accounted for the largest proportion (43.75%) in 2021, followed by Insulin Delivery (23.75%) and Artificial Pancreas (16.25%).

Of the global medical devices market value, the Diabetes Care Devices market held a 4% share worth $20bn in 2021 and is expected to reach $22.58bn by 2025.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Diabetes Care Devices development activity: Advanced stage of development leads

Devices at an advanced stage of development (in clinical trials, in the approval process, already approved in Europe or the rest of the world) accounted for 47.56% of medical devices in 2021, compared with 58.62% in 2020. The number of devices at the In Approval stage inclined by 80% in 2021, when compared with 2020.

The In Approval stage is considered to be the period where the manufacturer is waiting for final approval from regulators, following completion of the required development steps.

A decrease in products awaiting approval would indicate less new products entering the market in the coming months, while an increase indicates more devices entering the market, posing a market share threat to existing marketed devices.


Asia-Pacific tops pipeline Diabetes Care Devices products activity

Comparing the number of pipeline Diabetes Care Devices products activity in different regions of the globe, Asia-Pacific held the top position (40%) during 2021, followed by North America (37%), and Europe (22%).

On a country level, the US had the most pipeline Diabetes Care Devices during the year, representing the largest share (40%) of Diabetes Care pipeline products. In second place was China (25%), followed by Japan (9%).

New pipeline Diabetes Care medical devices: Expected to be approved by 2025

According to GlobalData, approximately 55% of pipeline Diabetes Care Devices in 2021 were expected to receive regulatory approval by the end of 2025. The leading categories for devices expected to receive regulatory approval by the end of 2025 was Blood Glucose Meters, at 15% of devices. Differences in regulatory approval timelines reflect the stage of development for a device, the device complexity or risk categorization (or device class) or if there are changes in regulatory oversight.

MicroTech Medical Co Ltd tops Diabetes Care Devices development in 2021

According to GlobalData, top ten medical device companies accounted for 36.25% of pipeline Diabetes Care Devices activity during 2021. The leading company for developing Diabetes Care Devices was MicroTech Medical Co Ltd with 11.25%, followed by Tandem Diabetes Care Inc at 5%.

Companies launching new medical devices are more likely to disrupt existing market share or are better able to defend existing share.

Company-developed pipeline products lead Diabetes Care Devices in development

Looking at the share of activity in terms of Diabetes Care pipeline products developers, company-developed pipeline products accounted for an 80% share of the Diabetes Care medical devices market, while institute-developed pipeline products held the remaining share.

The monthly average for 2021 saw company-developed Diabetes Care pipeline products account for 80% of pipeline products and institute-developed pipeline products account for 20%.

The medical devices pipeline data used in this article were extracted from Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. Pipeline Products database covers all medical devices which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. Pipeline products are covered from various authenticated sources like company websites, SEC filings, conference presentations, analyst presentations, news releases, grants etc. The information is collected by following systematic research techniques and proprietary methodology.